Inhibition of HIV-1 infection with curcumin conjugated PEG-citrate dendrimer; a new nano formulation
Open Access
- 2 October 2024
- journal article
- research article
- Published by Springer Nature in BMC Complementary Medicine and Therapies
- Vol. 24 (1) , 1-15
Abstract
Nano-drug delivery systems have become a promising approach to overcoming problems such as low solubility and cellular uptake of drugs. Along with various delivery devices, dendrimers are widely used through their unique features. PEG-citrate dendrimers are biocompatible and nontoxic, with the ability to improve drug solubility. Curcumin, a naturally occurring polyphenol, has multiple beneficial properties, such as antiviral activities. However, its optimum potential has been significantly hampered due to its poor water solubility, which leads to reduced bioavailability. So, the present study attempted to address this issue and investigate its antiviral effects against HIV-1. The G2 PEG-citrate dendrimer was synthesized. Then, curcumin was conjugated to it directly. FTIR, HNMR, DLS, and LCMS characterized the structure of products. The conjugate displayed an intense yellow color. In addition, increased aqueous solubility and cell permeability of curcumin were achieved based on flow cytometry results. So, it could be a suitable vehicle for improving the therapeutic applications of curcumin. Moreover, cell toxicity was assessed using XTT method. Ultimately, the SCR HIV system provided an opportunity to evaluate the level of HIV-1 inhibition by the curcumin-dendrimer conjugate using a p24 HIV ELISA kit. The results demonstrated a 50% up to 90% inhibition of HIV proliferation at 12 μm and 60 μm, respectively. Inhibition of HIV-1 at concentrations much lower than CC50 (300 µM) indicates a high potential of curcumin-dendrimer conjugate against this virus. Thereby, curcumin-dendrimer conjugate proves to be a promising tool to use in HIV-1 therapy.Keywords
This publication has 68 references indexed in Scilit:
- Molecular interactions between dimethoxycurcumin and Pamam dendrimer carriersInternational Journal of Pharmaceutics, 2007
- Curcumin–phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic study in ratsInternational Journal of Pharmaceutics, 2007
- Dendrimer–drug interactionsAdvanced Drug Delivery Reviews, 2005
- Targeted drug delivery with dendrimers: Comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complexAdvanced Drug Delivery Reviews, 2005
- Dendrimers of citric acid and poly (ethylene glycol) as the new drug-delivery agentsBiomaterials, 2005
- Curcumin, a Novel p300/CREB-binding Protein-specific Inhibitor of Acetyltransferase, Represses the Acetylation of Histone/Nonhistone Proteins and Histone Acetyltransferase-dependent Chromatin TranscriptionJournal of Biological Chemistry, 2004
- Dendrimers in drug researchChemical Society Reviews, 2003
- Curcumin and curcumin derivatives inhibit Tat-mediated transactivation of type 1 human immunodeficiency virus long terminal repeatResearch in Virology, 1998
- Curcumin Analogs with Altered Potencies against HIV-1 Integrase as Probes for Biochemical Mechanisms of Drug ActionJournal of Medicinal Chemistry, 1997
- Inhibition of the HIV-1 and HIV-2 proteases by curcumin and curcumin boron complexesBioorganic & Medicinal Chemistry, 1993